GW Pharmaceuticals PLC Company Profile (NASDAQ:GWPH)

GW Pharmaceuticals PLC trades on the NASDAQ under the ticker symbol "GWPH."

GW Pharmaceuticals PLC (NASDAQ:GWPH) posted its quarterly earnings data on Monday, August, 7th. The company reported ($2.07) earnings per share for the quarter, missing analysts' consensus estimates of ($1.73) by $0.34. The firm earned $3.14 million during the quarter, compared to analysts' expectations of $2.10 million. GW Pharmaceuticals PLC had a negative net margin of 1,384.41% and a negative return on equity of 28.80%. During the same period in the previous year, the company earned ($0.05) earnings per share. View GW Pharmaceuticals PLC's Earnings History.

GW Pharmaceuticals PLC is scheduled to release their next quarterly earnings announcement on Monday, December, 4th 2017. View Earnings Estimates for GW Pharmaceuticals PLC.

9 brokers have issued 1 year target prices for GW Pharmaceuticals PLC's stock. Their predictions range from $61.00 to $208.00. On average, they anticipate GW Pharmaceuticals PLC's share price to reach $151.25 in the next twelve months. View Analyst Ratings for GW Pharmaceuticals PLC.

Here are some recent quotes from research analysts about GW Pharmaceuticals PLC stock:

• 1. According to Zacks Investment Research, "GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company's lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain. It operates primarily in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc is based in Salisbury, the United Kingdom. " (7/24/2017)
• 2. Maxim Group analysts commented, "GW pharmaceuticals announced publication of data from the P3 study of Epidiolex (oral CBD, cannabidiol) in pediatric Dravet Syndrome in The New England Journal of Medicine (NEJM)." (5/25/2017)
• 3. Cantor Fitzgerald analysts commented, "NDA Filing Expected Mid-2017. GWPH expects to complete its filing in the U.S. shortly and noted two key portions in progress: 1) an integrated safety analysis of over 1,500 treated patients from clinical studies and the expanded access program, and 2) manufacturing data from the company’s manufacturing processes, including scaled materials. These elements will be the two determining factors of the timing of the NDA submission, which is expected in the middle of the year. Following the U.S. submission, GW expects to submit its MAA filing in 2H17 and plans to meet with the EMA in the near term. Pre-commercialization Activities Intensify. Greenwich Biosciences, the U.S. subsidiary of GW, is progressing with a pre-commercial strategy of expanding its team for the drug launch of Epidiolex. GW guided for a commercial team consisting of 15 medical-science liaisons by the end of 2017 and a sales force of 50-60 sales representatives to reach 4,000-5,000 targeted U.S. physicians. In addition, the company has begun to engage payors on awareness of patient need, Epidiolex, and pricing. We believe these efforts will set a meaningful foundation for Epidiolex’s commercial launch, which we estimate will initiate in 2018. Model Update. Following F2Q17 financial results, we have updated our model to reflect recent quarterly results and future expectations of operational expenditures." (5/9/2017)

Some companies that are related to GW Pharmaceuticals PLC include Neurocrine Biosciences (NBIX), bluebird bio (BLUE), Clovis Oncology (CLVS), AveXis (AVXS), Juno Therapeutics (JUNO), Agios Pharmaceuticals (AGIO), BeiGene (BGNE), Intercept Pharmaceuticals (ICPT), China Biologic Products (CBPO), Ultragenyx Pharmaceutical (RARE), Spark Therapeutics (ONCE), Sarepta Therapeutics (SRPT), Loxo Oncology (LOXO), Prothena Corporation PLC (PRTA), Axovant Sciences (AXON), Aerie Pharmaceuticals (AERI), NovoCure Limited (NVCR) and Halozyme Therapeutics (HALO).

GW Pharmaceuticals PLC's management team includes the folowing people:

• Geoffrey W. Guy, Executive Chairman of the Board
• Justin Gover, Chief Executive Officer, Director
• Adam David George, Chief Financial Officer, Company Secretary, Director
• Christopher John Tovey, Chief Operating Officer, Executive Director
• Julian S. Gangolli, Executive Director
• James Julian Noble, Non-Executive Deputy Chairman of the Board, Senior Independent Director
• Cabot Brown, Non-Executive Independent Director
• Thomas Gerard Lynch, Non-Executive Independent Director

GW Pharmaceuticals PLC's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Capital Research Global Investors (11.94%), Prudential PLC (7.76%), FMR LLC (4.56%), Janus Henderson Group PLC (2.76%), Capital World Investors (2.67%) and Jennison Associates LLC (1.94%). View Institutional Ownership Trends for GW Pharmaceuticals PLC.

GW Pharmaceuticals PLC's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Franklin Resources Inc., Prudential PLC, Tocqueville Asset Management L.P., Van ECK Associates Corp, Profit Investment Management LLC, Airain ltd and Sivik Global Healthcare LLC. View Insider Buying and Selling for GW Pharmaceuticals PLC.

GW Pharmaceuticals PLC's stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Redmile Group LLC, Employees Retirement System of Texas, Pictet Asset Management Ltd., Capital World Investors, Alliancebernstein L.P., Victory Capital Management Inc. and Jennison Associates LLC. View Insider Buying and Selling for GW Pharmaceuticals PLC.

Shares of GW Pharmaceuticals PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of GW Pharmaceuticals PLC stock can currently be purchased for approximately $99.62.